Insider Transactions in Q2 2023 at Travere Therapeutics, Inc. (TVTX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2023
|
Ron Squarer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+16.74%
|
-
|
|
May 17
2023
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+22.22%
|
-
|
|
May 17
2023
|
Gary A Lyons |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.18%
|
-
|
|
May 17
2023
|
John A Orwin |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+16.74%
|
-
|
|
May 17
2023
|
Jeffrey A Meckler |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+5.7%
|
-
|
|
May 17
2023
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+26.09%
|
-
|
|
May 17
2023
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+9.57%
|
-
|
|
May 17
2023
|
Sandra Poole |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+20.93%
|
-
|
|
May 17
2023
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+15.52%
|
-
|
|
May 11
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
122
-0.29%
|
$1,952
$16.12 P/Share
|
|
May 10
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
825
-1.44%
|
$13,200
$16.59 P/Share
|
|
May 10
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
455
-0.88%
|
$7,280
$16.59 P/Share
|
|
May 10
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
436
-1.02%
|
$6,976
$16.59 P/Share
|
|
May 10
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
825
-1.37%
|
$13,200
$16.59 P/Share
|
|
Apr 11
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
47
-0.09%
|
$987
$21.49 P/Share
|